--- title: "Selank | PepTracker Pro" url: https://peptrackerpro.com/peptides/selank description: "A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Selank Medium Evidence A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. Aliases TP-7 +1 more Evidence Medium Evidence Last Updated 2026-05-08 Reading Time 2 min ## What It Is Selank is a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetic analog of the immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. It has been studied for anxiolytic, nootropic, and immunomodulatory effects. In 2026, laboratory programs are examining how Selank interacts at the receptor level within the BDNF-TrkB and GABAergic signaling systems, with improved analytical instrumentation making preclinical research more precise and reproducible. Advances in nasal and transdermal delivery mechanisms have also improved bioavailability studies. Selank is commonly studied alongside Semax in cognitive peptide research stacks. It is registered as an anxiolytic in Russia but has no FDA approval and is not currently scheduled for PCAC review in the July 2026 sessions. Also known as: TP-7, Selanc ## Regulatory Status Category 1 — Bulk Compounding Returned to Category 1 compounding eligibility under FDA's February 2026 reclassification. May be compounded by 503A/503B pharmacies under physician prescription. Effective: February 2026 View FDA Source (https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding) ## Evidence Snapshot Medium Evidence Low Medium High ## Commonly Discussed Benefits Anxiety Relief: https://peptrackerpro.com/benefits/anxiety-relief Mood: https://peptrackerpro.com/benefits/mood Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Immune Support: https://peptrackerpro.com/benefits/immune-support Researching Selank? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=selank) ## Safety & Cautions - Approved in Russia but not FDA-approved in the US - Most research published in Russian-language journals - Long-term Western clinical data limited - Discuss with a healthcare provider ## Comparisons See how Selank compares to related peptides: Selank vs DSIP: https://peptrackerpro.com/compare/selank-vs-dsip Selank vs P21: https://peptrackerpro.com/compare/selank-vs-p21 Selank vs Semax: https://peptrackerpro.com/compare/selank-vs-semax Selank vs Trontinemab: https://peptrackerpro.com/compare/selank-vs-trontinemab ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Zozulya AA. et al. — Selank (TP-7): neuropsychotropic properties. Bull Exp Biol Med. 2008 PubMed (https://pubmed.ncbi.nlm.nih.gov/) 2. [2] Addiction Recovery Peptides 2026 Update — RealPeptides PubMed (https://www.realpeptides.co/addiction-recovery-peptides-2026-update/) ### Keep researching in the app - Log Selank to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=selank Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### DSIP Low Evidence A neuropeptide studied for its role in sleep regulation and stress modulation. Sleep: https://peptrackerpro.com/benefits/sleep Mood: https://peptrackerpro.com/benefits/mood Anxiety Relief: https://peptrackerpro.com/benefits/anxiety-relief Pain Relief: https://peptrackerpro.com/benefits/pain-relief View Details: https://peptrackerpro.com/peptides/dsip \+ Compare: https://peptrackerpro.com/compare?select=dsip Track in App: https://app.peptrackerpro.com/?add=dsip ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/p21 \+ Compare: https://peptrackerpro.com/compare?select=p21 Track in App: https://app.peptrackerpro.com/?add=p21 ### Semax Medium Evidence A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Mood: https://peptrackerpro.com/benefits/mood Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/semax \+ Compare: https://peptrackerpro.com/compare?select=semax Track in App: https://app.peptrackerpro.com/?add=semax ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. View Details: https://peptrackerpro.com/peptides/trontinemab \+ Compare: https://peptrackerpro.com/compare?select=trontinemab Track in App: https://app.peptrackerpro.com/?add=trontinemab ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Selank", "description": "A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.", "url": "https://peptrackerpro.com/peptides/selank", "lastReviewed": "2026-05-08", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Selank", "item": "https://peptrackerpro.com/peptides/selank" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching non-benzodiazepine anxiolytics?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } }, { "@type": "Question", "name": "Those interested in nootropic peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } }, { "@type": "Question", "name": "Individuals exploring immune-modulating compounds?", "acceptedAnswer": { "@type": "Answer", "text": "Selank is a research peptide studied in preclinical models. A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties." } } ] } ] ```